BACKGROUND AND PURPOSE:
[18F]-fluoroestradiol (FES) is a novel molecular imaging radiopharmaceutical that has demonstrated promise in the staging of ER-positive brain metastases. Our aim was to determine if hybrid [18F] FES brain PET/MRI is superior to conventional brain MRI alone for detecting estrogen receptor (ER)–positive brain and calvarial metastases, compare limited [18F] FES brain PET with vertex-to-below the knees [18F] FES PET results, and determine the impact of [18F] FES brain …